Mirikizumab
id:
mirikizumab-232-3342801
title:
Mirikizumab
text:
Mirikizumab, sold under the brand name Omvoh, is a monoclonal antibody used for the treatment of ulcerative colitis. It is designed to attach to interleukin-23 (IL-23) and block its activity. The most common side effects include upper respiratory tract infections, headache, rash and reactions at the site of injection. Mirikizumab was approved for medical use in the European Union in May 2023, and in the United States in October 2023.
brand slug:
wiki
category slug:
encyclopedia
description:
Medication
original url:
https://en.wikipedia.org/wiki/Mirikizumab
date created:
date modified:
2024-03-10T06:00:13Z
main entity:
{"identifier":"Q55641096","url":"https://www.wikidata.org/entity/Q55641096"}
image:
fields total:
13
integrity:
14